MDxHealth S.A.
NASDAQ:MDXHMedical - Diagnostics & Research
-$0.03 today
- Market cap
- $57.59M
- Beta
- 0.38
- P/E (TTM)
- -1.0
- EPS (TTM)
- -$0.58
Volume 0.65M
Average 4.27M
MDXH Cash & Equivalents
Cash on hand and highly liquid investments that can be converted to cash almost immediately.
MDxHealth S.A.NASDAQ: MDXH
Cash & Equivalents · Q2 FY2026 · quarter ended Jun 2026
Cash & equivalents falls 41.5% from a year ago
Cash & equivalents stood at $19.21M at the end of Q2 FY2026, down 41.5% from a year earlier. Over 3 fiscal years it compounded at +23.3% a year.
Context
- Cash & equivalents amounted to 14.5% of total assets at the end of Q2 FY2026, down 8.8 pp from a year earlier.
- Cash & equivalents increased in 2 of the last 3 fiscal years.
What to watch
Whether cash & equivalents keeps falling in the next quarterly balance sheet after a -41.5% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Cash & Equivalents history
USD · from the balance sheet
- Latest · FY2025
- 29.03M USD
- Year-over-year change
- -38.0%
- 4-year CAGR
- -16.1%
| Period | Period end | Cash & Equivalents | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 29.03M | -38.0% |
| FY2024 | 2024-12-31 | 46.8M | +109.1% |
| FY2023 | 2023-12-31 | 22.38M | +44.4% |
| FY2022 | 2022-12-31 | 15.5M | -73.5% |
| FY2021 | 2021-12-31 | 58.5M | — |
Cash & Equivalents vs competitors
How MDXH compares with its peers on the latest reported figures
- MDXH's Jun 2026 cash & equivalents of $19.21M is the 8th highest of the 11 companies compared; the peer median is $29.89M.
- Its year-over-year change of -41.5% is the 10th highest of 11, against a peer median of +32.1%.
- Cash & equivalents amounts to 14.5% of total assets for MDXH, versus a peer median of 13.8%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
ZURAZura Bio Limited | Mar 2026 | $225.59M | +32.3% | +311.8% | 98.7% |
| Jun 2026 | $145.54M | -5.9% | -15.4% | 10.8% | |
| Mar 2026 | $47.32M | +31.9% | +21.0% | 0.0% | |
| Mar 2026 | $36.18M | -52.7% | -55.5% | 9.9% | |
| Mar 2026 | $31.12M | +32.9% | +3.7% | 13.2% | |
| Mar 2026 | $28.66M | -5.6% | -23.9% | 14.4% | |
| Mar 2026 | $21.51M | +92.2% | -19.8% | 41.4% | |
| Jun 2026 | $19.21M | -41.5% | +23.3% | 14.5% | |
| Mar 2026 | $14.62M | +37.9% | +16.1% | 27.1% | |
| Mar 2026 | $11.49M | +80.4% | — | 7.2% | |
| Mar 2026 | $10.78M | +26.8% | +118.1% | 29.1% | |
| Peer median (excluding MDXH) | $29.89M | +32.1% | +3.7% | 13.8% | |
Competitors are the stored peer set for MDXH. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 58.5M | 15.5M | 22.38M | 46.8M | 29.03M |
| Short-term Investments | 89K | 101K | 0 | 0 | 0 |
| Net Receivables | 4.58M | 9.36M | 11.27M | 14.53M | 14.73M |
| Inventory | 1.91M | 2.33M | 2.78M | 3.87M | 6.74M |
| Other Current Assets | 504K | 151K | 146K | 135K | 940K |
| Total Current Assets | 66.61M | 29.15M | 38.16M | 66.9M | 53.41M |
| Property, Plant & Equipment (Net) | 5.02M | 7.89M | 9.95M | 12.98M | 14.68M |
| Goodwill | 0 | 35.93M | 35.93M | 35.93M | 38.95M |
| Intangible Assets | 3.45M | 46.17M | 44.34M | 40.59M | 39.42M |
| Long-term Investments | 0 | 0 | 763K | 936K | 1.5M |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 1 | 0 | 0 | 0 | 0 |
| Total Non-current Assets | 8.47M | 89.99M | 90.97M | 90.43M | 94.54M |
| Total Assets | 75.07M | 119.14M | 129.13M | 157.33M | 147.95M |
| Account Payables | 7.46M | 10.18M | 8.81M | 8M | 10.33M |
| Short-term Debt | 4.44M | 616K | 643K | 324K | 1.9M |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 0 | 0 | 472K | 0 | 0 |
| Other Current Liabilities | 961K | 2.33M | 2.9M | 26.41M | 37.31M |
| Total Current Liabilities | 16.43M | 18.28M | 19.52M | 42.66M | 49.53M |
| Long-term Debt | 7.65M | 34.91M | 35.56M | 50.97M | 84.71M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 1.47M | 53.54M | 63.26M | 41.45M | 17.3M |
| Total Non-current Liabilities | 11.74M | 91.54M | 102.4M | 99.83M | 110.51M |
| Total Liabilities | 28.17M | 109.82M | 121.92M | 142.49M | 160.05M |
| Common Stock | 143.42M | 148.42M | 173.93M | 214.67M | 219.21M |
| Retained Earnings | (244.3M) | (288.35M) | (331.45M) | (369.52M) | (403.03M) |
| Accumulated OCI | (5.4M) | (3.94M) | 11.55M | (615K) | 18.55M |
| Other Stockholders Equity | 0 | 0 | 0 | 17.12M | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 46.9M | 9.32M | 7.21M | 14.84M | (12.09M) |
| Total Debt | 15.56M | 39.79M | 41.27M | 60.06M | 95.11M |
| Net Debt | (42.94M) | 24.29M | 18.89M | 13.27M | 66.08M |
MDxHealth S.A.
NASDAQ:MDXH
Intrinsic Alpha fair value
Locked
Current Price
$0.60
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.